contraindications for glp-1 agonists Contraindications, warnings, and precautions of receptor 367. GLP-1 Agonists: Clinical Implementation
Description
Retatrutide produces approximately double the heart rate increase of semaglutide
As for CV death, Fig
infants, 63%
Large-scale, randomized controlled trials with robust stratification of HFpEF phenotypes are needed to confirm the efficacy and safety of GLP-1RAs in this population
The Semaglutide Treatment Effect in People with obesity (STEP) program, a phase III randomized clinical trial (RCT), was conducted in patients with T2D, obesity, and various metabolic disorders
R.JensenJ
